Lifestyle Counseling Frequency, CV Outcomes Linked in Diabetes
More frequent counseling tied to lower incidence of death, CV events in adults with diabetes
Study Explores Dose Ranges for Efpeglenatide in Early T2DM
Safety profile consistent with other long-acting glucagon-like peptide 1 receptor agonists
BP, Waist Circumference, Lipids Should Be Measured Regularly
Lifestyle management should be priority for prevention of ASCVD, T2DM in patients at metabolic risk
Brand-Brand Competition Has Not Cut Prices in Pharma Market
Review shows evidence that brand-brand competition was mediated by quality of competing drugs
Mediterranean Eating Plan May Help Keep T2DM Patients Off Meds
Med-EatPlan plus extra virgin olive oil linked to lower risk for starting first glucose-lowering medication
Early Menarche Linked to Risk for T2DM in Rural Chinese Women
Risk for diabetes increased for early menarche group; association partially mediated by adult BMI
July 2019 Briefing – Diabetes & Endocrinology
Here are what the editors at HealthDay consider to be the most important developments in Diabetes & Endocrinology for July 2019. This roundup includes...
Trump Admin Announces Plan to Allow Drug Imports From Canada
Plan will start by exploring options for importing certain prescription drugs to lower costs for Americans
Childhood BMI, HDL-C Variability May Up Later-Life Diabetes Risk
Greater variability tied to higher risk, independent of mean levels for BMI, HDL cholesterol in childhood
Oral Semaglutide Reduces HbA1c, Weight in Patients With T2DM
Semaglutide has a safety and tolerability profile consistent with other GLP-1 receptor agonists
